Literature DB >> 7691240

Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system.

P W Johnson1, S M Watt, D R Betts, D Davies, S Jordan, A J Norton, T A Lister.   

Abstract

Low-grade follicular non-Hodgkin's lymphomas are characterized by the presence of a t(14;18) chromosomal translocation that results in deregulation of the B-cell lymphoma (Bcl-2) gene. Studies in cell lines and transgenic animal models have suggested that this results in the suppression of apoptotic cell death in germinal centers. B lymphocytes from normal germinal centers and lymph nodes infiltrated by follicular lymphoma were isolated by immunomagnetic depletion of cells bearing CD4, CD8, or slgD for study in vitro. Follicular lymphoma cells expressing Bcl-2 protein were shown to resist apoptosis after isolation, and could be induced to proliferate in a culture system previously described for the growth of normal B lymphocytes. By the use of a mouse fibroblast monolayer transfected with the CDw32 Fc receptor to present CD40 monoclonal antibody in the presence of interleukin-4, prolonged culture was possible. Karyotypic analysis of cultured lymphoma cells showed the t(14;18) translocation, with clonal identity confirmed by polymerase chain reaction amplification of the breakpoints and direct sequence analysis. These findings support the hypothesis that resistance to apoptosis is an influence on the initiation of follicular lymphoma, and provide a novel means of studying in vitro the intercellular reactions that may be important in progression of the disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691240

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  21 in total

1.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

3.  Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance.

Authors:  Marek Mraz; Clive S Zent; Amy K Church; Diane F Jelinek; Xiaosheng Wu; Sarka Pospisilova; Stephen M Ansell; Anne J Novak; Neil E Kay; Thomas E Witzig; Grzegorz S Nowakowski
Journal:  Br J Haematol       Date:  2011-07-12       Impact factor: 6.998

4.  CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.

Authors:  A Carbone; A Gloghini; H J Gruss; A Pinto
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

5.  CD40·FasL and CTLA-4·FasL fusion proteins induce apoptosis in malignant cell lines by dual signaling.

Authors:  Ariel Orbach; Jacob Rachmilewitz; Noam Shani; Yonatan Isenberg; Miriam Parnas; Jui-Han Huang; Mark L Tykocinski; Michal Dranitzki-Elhalel
Journal:  Am J Pathol       Date:  2010-11-18       Impact factor: 4.307

6.  IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Giulio Fraternali-Orcioni; Anna Corcione; Beatrice Belmonte; Jean Louis Ravetti; Claudio Tripodo; Domenico Ribatti; Vito Pistoia
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

7.  The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Birgitta Sander; Daphne de Jong; Andreas Rosenwald; Wanling Xie; Olga Balagué; Maria Calaminici; Joaquim Carreras; Philippe Gaulard; John Gribben; Anton Hagenbeek; Marie José Kersten; Thierry Jo Molina; Abigail Lee; Santiago Montes-Moreno; German Ott; John Raemaekers; Gilles Salles; Laurie Sehn; Christoph Thorns; Björn E Wahlin; Randy D Gascoyne; Edie Weller
Journal:  Haematologica       Date:  2014-02-07       Impact factor: 9.941

Review 8.  The tumour microenvironment in B cell lymphomas.

Authors:  David W Scott; Randy D Gascoyne
Journal:  Nat Rev Cancer       Date:  2014-07-10       Impact factor: 60.716

9.  The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.

Authors:  E Ferretti; C Tripodo; G Pagnan; C Guarnotta; D Marimpietri; M V Corrias; D Ribatti; S Zupo; G Fraternali-Orcioni; J L Ravetti; V Pistoia; A Corcione
Journal:  Leukemia       Date:  2014-10-06       Impact factor: 11.528

10.  Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma.

Authors:  Elisa Ferretti; Emma Di Carlo; Emanuela Ognio; Carla Guarnotta; Francesco Bertoni; Anna Corcione; Ignazia Prigione; Giulio Fraternali-Orcioni; Domenico Ribatti; Jean Louis Ravetti; Maurilio Ponzoni; Claudio Tripodo; Vito Pistoia
Journal:  Oncoimmunology       Date:  2015-06-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.